Astec LifeSciences Limited has published its audited financial results for the quarter and financial year ended March 31, 2026, following approval by the Board of Directors on April 27, 2026. The results were disclosed through newspaper publications on April 28, 2026, in Business Standard (English) and Mumbai Lakshdeep (Marathi), as required under SEBI regulations.

Financial Performance Overview

The company's financial performance for FY26 showed mixed results with increased revenue but continued losses. Total income from operations reached ₹45,321.65 lakhs for the full year, representing growth from ₹38,693.22 lakhs in the previous financial year.

Capital Structure and Financial Position

The company's capital structure showed significant changes during the year, with equity share capital increasing to ₹2,228.22 lakhs from ₹1,961.14 lakhs in the previous year. Net worth improved substantially to ₹39,091.84 lakhs compared to ₹23,501.65 lakhs in FY25.

Earnings Per Share and Key Ratios

The company reported negative earnings per share for both basic and diluted calculations. For FY26, the loss per share stood at ₹37.79 compared to ₹68.71 in the previous year, showing improvement despite continued losses.

Key Financial Ratios:

• Debt Service Coverage Ratio: (0.01) for FY26 vs (1.15) for FY25
• Interest Service Coverage Ratio: (0.04) for FY26 vs (1.48) for FY25
• Capital Redemption Reserve: ₹0.30 lakhs (unchanged)

Regulatory Compliance

The financial results disclosure was made pursuant to Regulation 30 read with Schedule III and Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company secretary Tejashree Pradhan signed the compliance documents on April 28, 2026, ensuring proper regulatory adherence for the BSE-listed company with scrip code 533138.

ASTEC LifeSciences Limited has announced comprehensive changes to its board structure following a meeting held on April 13, 2026, marking a significant transition in the company's leadership framework under Regulation 30 of SEBI Listing Obligations.

Leadership Transition at the Top

The board noted the retirement of Mr. Nadir Godrej from his position as Chairperson and Director, effective from the close of business hours on April 13, 2026. Mr. Godrej, who will turn 75 in August 2026, expressed his intention to step down in his retirement letter, stating his confidence in the leadership team's ability to create sustainable long-term value for stakeholders.

New Chairman Appointment

The board has appointed Mr. Vishal Sharma as Additional Director (Non-Executive, Non-Independent) and Chairperson, effective from the close of business hours on April 13, 2026, subject to shareholder approval. Mr. Sharma brings extensive experience as Executive Director & Chief Executive Officer (Chemicals) of Godrej Industries Limited, the ultimate holding company.

Managing Director Transition

Mr. Burjis N. Godrej has resigned from his position as Managing Director with immediate effect, citing his intention to have deeper involvement in Godrej Agrovet Limited, the parent company. He will continue serving on the board as a Non-Executive Director, subject to shareholder approval.

Additional Board Appointments

The board has approved two additional appointments to strengthen its composition:

Mr. Mathew Eipe has been appointed as Additional Non-Executive Independent Director for a term from April 13, 2026, to June 6, 2027, subject to shareholder approval. He serves as Independent Director of Godrej Industries Limited and brings extensive experience from his tenure with the Godrej Group, including leadership of the Chemicals business until his retirement in 2013.

Mr. Arijit Mukherjee has been appointed as Additional Executive Director & Chief Operating Officer for a three-year term from April 13, 2026, to April 12, 2029, subject to shareholder approval. Currently serving as Chief Operating Officer, he brings over 20 years of experience in the Agri Inputs business and has been associated with Godrej Agrovet Limited since 2005.

Board Composition and Regulatory Compliance

Following these changes, the board will comprise 10 directors, maintaining balanced governance with 5 independent directors (50%) and 5 non-independent directors (50%). All appointments are subject to shareholder approval and comply with applicable provisions of the Companies Act, 2013, and SEBI Listing Regulations.

The company has confirmed that all newly appointed directors are eligible under relevant regulations and are not debarred from holding directorship positions by SEBI or any other authority. The board meeting commenced at 4:00 p.m. and concluded at 4:14 p.m. on April 13, 2026.